Anti-CD19 CART (C-CAR011) Therapy for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma.
10.19746/j.cnki.issn.1009-2137.2021.04.019
- Author:
Lu ZHANG
1
;
Yan ZHANG
1
;
Dao-Bin ZHOU
2
Author Information
1. Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
2. Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China,E-mail: zhoudb@pumch.cn.
- Publication Type:Journal Article
- MeSH:
Antigens, CD19/therapeutic use*;
Antineoplastic Combined Chemotherapy Protocols;
B-Lymphocytes;
Female;
Humans;
Lymphoma, Follicular;
Lymphoma, Large B-Cell, Diffuse;
Male;
Middle Aged;
Neoplasm Recurrence, Local/drug therapy*;
Treatment Outcome
- From:
Journal of Experimental Hematology
2021;29(4):1141-1147
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To evaluate the safety and efficacy of C-CAR011 in the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL) patients.
METHODS:B-NHL patients treated with C-CAR011 infusion following lympho-depletion were enrolled. All the patients were followed up for 1 year after C-CAR011 treatment(5.0×10
RESULTS:The ratio of the male and female of 6 patients was 1∶1, and the patients were treated with C-CAR011 at a dose of 5.0×10
CONCLUSION:C-CAR011 is a safe treatment option for R/R B-NHL; some patients could achieve long-term sustained responses after C-CAR011 infusion（ClinicalTiral.gov number, NCT03483688）.
